Measuring What Matters
Morgan Bron(Neurocrine Biosciences (United States)), Christoph U. Correll(American Academy of Child and Adolescent Psychiatry), Hui Zhang(Neurocrine Biosciences (United States)), Ashok Parameswaran(Neurocrine Biosciences (United States)), Susan D. Mathias(Health Outcomes Solutions (United States)), Donald E. Stull(IQVIA (United States)), M. Mercedes Perez-Rodriguez(Icahn School of Medicine at Mount Sinai), Eduardo Dunayevich(Neurocrine Biosciences (United States)), Michelle Turner(Health Outcomes Solutions (United States)), Dawn Vanderhoef(Neurocrine Biosciences (United States))
Cited by 0
Related Papers
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2010|1k
Optimal recall periods for patient-reported outcomes: challenges and potential solutions
|Current Medical Research and Opinion|2009|413
Improved quality of life for romiplostim‐treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo‐controlled trials
|British Journal of Haematology|2008|146
Measurement and the Analysis of Burden
|Research on Aging|1985|142